Apollo Medical Holdings Reports Strong Fiscal 2014 First Quarter Results
Net Revenues Climb 53% to $2.45 Million Compared to $1.63 Million for Same Three Month Reporting Period in Prior Fiscal Year
GLENDALE, Calif., June 14, 2013 /PRNewswire/ – Apollo Medical Holdings, Inc. (“ApolloMed”) (OTCQB: AMEH), an integrated physician-driven healthcare delivery company that puts ‘Patients First,’ today announced its fiscal 2014 first quarter results for the three months ended April 30, 2013.
Financial Highlights for Three Months Ended April 30, 2013 Compared to Three Months Ended April 30, 2012:
- Net revenues rose 53%, increasing to $2.45 million from $1.63 million. The increase was largely attributable to new hospital contracts, increased same-market area growth and expansion of services with existing medical group clients at new hospitals.
- Gross profit margin improved to 24% from 19%.
- Loss from operations increased to $711,972 compared to loss from operations of $53,153, due largely to an increase in costs relating to stock-based compensation totaling $519,092, coupled with increased spending associated with strategic growth initiatives relating to ApolloMed ACO and its new business unit, Maverick Medical Group.
- Non-GAAP* Adjusted EBITDA loss totaled $82,094 compared to EBITDA of $55,772.
As of April 30, 2013, ApolloMed had $1.58 million in cash and cash equivalents, $1.32 million in accounts receivable and total stockholders’ deficit of approximately $935,000. For the first three months of fiscal 2014, the Company’s operating activities provided $12,972 in net cash, which compared to $131,160 in net cash used in operations in the same three months ended April 30, 2012.
ApolloMed CEO Warren Hosseinion, M.D. stated, “Our strong revenue growth in the first fiscal quarter points to the success we continue to achieve in executing our growth strategies and tactical expansion initiatives – all of which are centered on establishing ApolloMed as a top-tier performing integrated healthcare company in the rapidly evolving healthcare industry.”
Continuing, he added, “With Accountable Care Organizations expected to play a significant role in reshaping how care is delivered in this country, ApolloMed ACO is hard at work developing innovative, coordinated care models that best leverage our noted hospitalist experience and expertise and the strength and depth of our newly launched Independent Physician Association, Maverick Medical Group. We believe fiscal 2014 will indeed prove to be a banner year for ApolloMed and based on our performance, thus far, we’re off to a very good start.”
For more details on ApolloMed’s fiscal 2014 first quarter results, please refer to the Company’s 10-Q filed with the U.S. Securities Exchange Commission and accessible at www.sec.gov.
FINANCIAL CHARTS TO FOLLOW
APOLLO MEDICAL HOLDINGS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) ASSETS April 30, 2013 January 31, 2013 --------------- ---------------- CURRENT ASSETS Cash and cash equivalents $1,575,500 $1,176,727 Accounts receivable, net 1,320,087 1,582,505 Due from affiliates - 5,648 Prepaid expenses 85,200 72,628 Deferred financing costs, current 67,113 34,614 ----------------- Total current assets 3,047,900 2,872,122 Deferred financing costs, non-current 211,375 218,640 Property and equipment, net 64,689 68,142 Goodwill 33,200 33,200 Other assets 30,981 30,981 TOTAL ASSETS $3,388,145 $3,223,085 ========== ========== LIABILITIES AND STOCKHOLDERS' DEFICIT CURRENT LIABILITIES: Accounts payable and accrued liabilities $863,782 $950,651 Notes payable 594,745 594,765 Stock issuable 828,709 159,334 -------------- Total current liabilities 2,287,236 1,704,750 Convertible notes payable, net 2,035,828 1,909,714 Total liabilities 4,323,064 3,614,464 ----------------- STOCKHOLDERS' DEFICIT Preferred stock, par value $0.001 ; 5,000,000 shares authorized; none issued - - Common Stock, par value $0.001; 100,000,000 shares authorized, 34,843,441 shares issued and outstanding as of April 30, 2013 and January 31, 2013, respectively 34,844 34,844 Prepaid consulting (554,050) (616,014) Additional paid-in- capital 11,489,102 11,248,566 Accumulated deficit (11,871,387) (11,022,272) Total (901,491) (354,876) ----- Non-controlling interest (33,428) (36,503) Total stockholders' deficit (934,919) (391,379) ----------------- TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT $3,388,145 $3,223,085
APOLLO MEDICAL HOLDINGS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Three months ended April 30, 2013 2012 ---- ---- NET REVENUES $2,446,566 $1,631,844 COST OF SERVICES 1,860,493 1,328,659 --------- --------- GROSS PROFIT 586,073 303,185 Operating expenses: General and administrative 1,291,393 351,547 Depreciation 6,652 4,791 Total operating expenses 1,298,045 356,338 --------- ------- LOSS FROM OPERATIONS (711,972) (53,153) Other income (expense) Gain on change in fair value of derivative liabilities - 123,838 Interest expense (127,493) (224,036) Other expense (246) (5) Total other expenses (127,739) (100,203) -------- -------- LOSS BEFORE INCOME TAXES (839,711) (153,356) Provision for Income Tax 9,404 4,000 NET LOSS $(849,115) $(157,356) ========= ========= WEIGHTED AVERAGE SHARES OF COMMON STOCK OUTSTANDING -BASIC AND DILUTED 34,843,441 29,965,878 ========== ========== BASIC AND DILUTED NET LOSS PER SHARE $(0.02) $(0.01) ====== ======
*APOLLO MEDICAL HOLDINGS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS - ADJUSTED EBITDA RECONCILIATION (UNAUDITED) Three months ended April 30, ------------------- 2013 2012 ---- ---- LOSS FROM OPERATIONS $(711,972) $(53,153) Depreciation and amortization expense 6,652 4,791 ----- ----- EBITDA (705,320) (48,362) Stock-based compensation expense 623,226 104,134 ADJUSTED EBITDA $(82,094) $55,772 ======== =======
*Use of Non-GAAP Financial Measures
In addition to containing results that are determined in accordance with accounting principles generally accepted in the United States of America (GAAP), this press release also contains non-GAAP financial measures. Adjusted EBITDA, as used in this press release, represents Loss from Operations before depreciation, adjusted for issuance of shares for service, stock option expense, amortization of debt discount and impairment of intangibles and losses on discontinued operations. Adjusted EBITDA is a key indicator used by management to evaluate operating performance. While adjusted EBITDA is not intended to replace any presentation included in the consolidated financial statements under GAAP and should not be considered an alternative to operating performance or an alternative to cash flow as a measure of liquidity, the Company believes this measure is useful to investors in assessing the Company’s ongoing operating performance and working capital requirements. This calculation may differ in method of calculation from similarly titled measures used by other companies. A reconciliation of adjusted EBITDA to the nearest comparable GAAP financial measure is included in the financial schedules accompanying this press release. The Non-GAAP financial measures, as well as other information in this press release, should be read in conjunction with the Company’s financial statements filed with the Securities and Exchange Commission.
About Apollo Medical Holdings, Inc. (ApolloMed)
Headquartered in Glendale, California and dedicated to putting the ‘Patient First,’ ApolloMed is a leading provider of physician-driven integrated healthcare management services, fueled by its commitment to provide exceptional multi-disciplinary care in the communities it serves in Southern and Central California. ApolloMed is addressing the healthcare needs of the nation’s largest population center by leveraging its integrated healthcare delivery platform comprised of three affiliated and complementary physician groups: ApolloMed Hospitalists, ApolloMed ACO (Accountable Care Organization) and Maverick Medical Group (Independent Physician Association). This platform combines hospitalist medicine, critical care medicine, case management and transition management that enable healthcare organizations to engage in performance payments for utilization efficiency, quality of care objectives and shared accountability arrangements. ApolloMed strives to improve medical outcomes with high quality, cost efficient care. For more information, please visit www.apollomed.net.
Forward Looking Statements
This press release may contain forward-looking statements, including information about management’s view of Apollo Medical Holdings, Inc. (“the Company”) future expectations, plans and prospects. In particular, when used in the preceding discussion, the words “believes,” “expects,” “intends,” “plans,” “anticipates,” or “may,” and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this press release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company’s future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by Apollo Medical Holdings, Inc.
For More Information, PLEASE CONTACT:
Kathy Addison, Chief Operating Officer
407-585-1080 or via email at AMEH@hanoverelite.com
SOURCE Apollo Medical Holdings, Inc.